Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>The effectiveness of trimethoprim/sulfamethoxazole (TMP/SMZ) for pneumocystis pneumonia (PCP) is limited with adverse events. Caspofungin, by inhibiting the cyst form of <i>Pneumocystis jirovecii</i>, may be an alternative therapy for PCP. However, the availability of clinical data about caspofungin combined with TMP/SMZ in the treatment of PCP in HIV‐infected patients is limited. Thus, we aimed to examine the clinical effectiveness and safety of caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in HIV‐infected patients. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>From January 2017 to December 2019, data of HIV‐infected patients with moderate‐to‐severe PCP who received either TMP/SMZ alone or caspofungin combined with TMP/SMZ as first‐line therapy were retrospectively reviewed to assess the effectiveness and safety of each regimen. The Kaplan–Meier curve and log‐rank test were used for survival analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A total of 278 patients met the criteria. The overall positive response rate of PCP treatment was 48.92%, and the overall all‐cause in‐hospital mortality rate was 33.09%. Patients who received combination therapy consisting of caspofungin and TMP/SMZ had a better positive response rate (59.44% <i>vs</i>. 37.78%, <i>P</i> < 0.001) and lower all‐cause in‐hospital mortality rate (24.48% <i>vs</i>. 42.22%, <i>P</i> = 0.003). Also, patients who received combination therapy had higher survival rate during a hospital stay (75.52% <i>vs</i>. 57.78%, <i>P</i> = 0.004), and those who received longer combination therapy were more likely to have higher survival rate (<i>P</i> = 0.042). We found that age (<i>P</i> = 0.019), CD4 cell count (<i>P</i> = 0.001) and therapeutic regimen (<i>P</i> = 0.002) were significant risk factors for all‐cause in‐hospital mortality rate in univariate analysis. In multivariate analysis, only CD4 cell count and therapeutic regimen were statistically significant factors associated with all‐cause in‐hospital mortality rate. Patients with a CD4 count of > 30 cells/µL and patients who received combination therapy consisting of caspofungin and TMP/SMZ were more likely to survive from PCP (<i>P</i> = 0.011 and <i>P</i> = 0.002, respectively). There were no additional severe adverse events caused by adding caspofungin. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>For HIV‐infected patients with moderate‐to‐severe PCP, combination therapy with caspofungin and TMP/SMZ is an effective and promising first‐line therapy with no greater number of adverse events compared with TMP/SMZ monotherapy. Patients who received caspofungin had better positive response rates and lower all‐cause in‐hospital mortality rates. Also, we recommend early initiation of caspofungin.</p></section>

Combined caspofungin and TMP-SMX treatment for PCP in AIDS patients

A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia

Efficacy of Caspofungin Combined with Trimethoprim/sulfamethoxazole As First-Line Therapy to Treat Non-Hiv Patients with Severe Pneumocystis Pneumonia.

Caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in patients with human immunodeficiency virus infection

Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection

Analysis of caspofungin combined with clindamycin for severe pneumocystis pneumonia

Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin

Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.

Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: A case report and literature review.

A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital

Trimethoprim-sulfamethoxazole combined with echinocandins versus trimethoprim-sulfamethoxazole alone for Pneumocystis pneumonia in patients without human immunodeficiency virus infection: A nationwide retrospective cohort study

Diagnostic Value of Fluorescence Real-Time PCR for Pneumocystis Pneumonia in AIDS Patients

Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation

Correlation between composite infections in acquired immune deficiency syndrome patients complicated with pneumocystis pneumonia and counts of CD4 + T cell

Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia.

A controlled clinical study of long course chemotherapy regimens combined with immunopotentiator in the treatment of multi-drug resistant pulmonary tuberculosis

Case Report: <i>Tropheryma whipplei</i> Hide in an AIDS Patient With <i>Pneumocystis</i> Pneumonia

Efficacy and safety of caspofungin for the treatment of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

[A Study on the Clinical Efficacy of a Combination Regimen with Levofloxacin and Capreomycin in the Treatment of Multi-Drug Resistant Pulmonary Tuberculosis].

[Efficacy of clindamycin-primaquine as the salvage treatment for pneumocystis pneumonia in non-HIV-infected patients]